Pre-eclampsia with new-onset systemic lupus erythematosus during pregnancy: A case report

Peng-Zhu Huang, Pei-Yang Du, Cha Han, Jun Xia, Chen Wang, Jie Li, Feng-Xia Xue

ORCID number: Peng-Zhu Huang (0000-0003-1432-7066); Pei-Yang Du (0000-0003-3194-4963); Cha Han (0000-0002-8090-7600); Jun Xia (0000-0001-5830-294X); Chen Wang (0000-0003-3995-4242); Jie Li (0000-0003-1219-5776); Feng-Xia Xue (0000-0001-9694-0061).

Author contributions: Huang PZ drafted the table and manuscript; Du PY searched the relevant literature and collected the data; Han C contributed to the design and revision of this study; Xia J edited and contributed to manuscript drafting; Wang C and Li J were the patient’s obstetricians and reviewed the literature; Xue FX revised the final manuscript.

Supported by the Natural Science Foundation of Tianjin Municipal Science and Technology Commission, No. 16JCYBJC26400

Informed consent statement: Written informed consent was obtained from the patient for publication of this report.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license.

Abstract

BACKGROUND
New-onset systemic lupus erythematosus (SLE) during pregnancy and in the postpartum period is rare, especially when complicated with pre-eclampsia, which is difficult to diagnose accurately. Here, we report a patient with new-onset SLE and antiphospholipid syndrome during pregnancy, which presented as pre-eclampsia at admission.

CASE SUMMARY
A 28-year-old primigravid woman was admitted to our hospital in the 27th wk of gestation with the primary diagnosis of severe pre-eclampsia. Although spasmolysis and antihypertensive therapy were administered since admission, the 24-h proteinuria of the 2nd day after admission reached 10311.0 mg. In the 47th h of admission, immunologic examinations revealed increased levels of anti-double stranded DNA antibody, anti-nuclear antibody, anti-cardiolipin antibody, anti-Sjögren’s syndrome-related antigen A antibody and anti-nucleosome antibody and decreased levels of complement C3 and C4. One hour later, ultrasonography of the lower limbs showed thrombus of the bilateral popliteal veins. The diagnosis of SLE and antiphospholipid syndrome was indicated. In the 54th h, the patient manifested with convulsion, dyspnea and blurred vision. Ten hours later, intrauterine death was revealed by ultrasonography. Emergent surgery consisting of inferior vena cava filter implantation and subsequent cesarean section was performed. Following glucocorticoid and anticoagulation therapy after delivery, the patient had an optimal response with improvements in symptoms and immunological markers.

CONCLUSION
Obstetricians should be aware of the symptoms and immunological examination results to distinguish pre-eclampsia and underlying SLE for optimal pregnancy outcomes.
INTRODUCTION

Systemic lupus erythematosus (SLE) is a rare autoimmune connective tissue disease involving multiple systems with the incidence of 1 to 10 per 100000 person-years and the prevalence of 20 to 70 per 100000[1]. Characterized by a strong female predisposition, SLE mainly affects women of reproductive age with a female-to-male ratio of approximately 9:1, which is largely thought to be due to the effect of female sex hormones on the immune system[2]. Pregnant women with SLE have a higher risk of complications than non-pregnant women. The risk of pre-eclampsia in pregnant women with SLE is 3-5 times higher, and SLE complicated with pre-eclampsia accounts for 16%-30% of all SLE pregnancies. Up to 25% of SLE patients will develop pre-eclampsia, although this ratio is only 5% in the general population[3]. Distinguishing between pre-eclampsia and SLE is challenging as the clinical manifestations of pre-eclampsia can sometimes mimic SLE, and the management of the two conditions emphasizes the expectant delivery and medication, respectively. Here we present a case of pre-eclampsia complicated with new-onset SLE during pregnancy and review the literature of similar cases.

CASE PRESENTATION

Chief complaints

On January 8, 2019, a 28-year-old primigravid woman at 27th wk of gestation was admitted to our hospital with edema of both lower limbs for 4 d, elevated blood pressure (150/98 mmHg) and proteinuria (4+) for 1 d.

History of present illness

Examination results on the tenth week of gestation showed blood pressure of 110/60 mmHg, negative urine protein and a platelet count of 234 × 10⁹/L. Antenatal checkup was conducted regularly and showed normal outcomes except for edema in both limbs, hypertension and proteinuria before admission.

History of past illness

There was no history of past illness.

Personal and family history

She was married without the history of pregnancy or contraception. Her spouse was healthy and her family history was unremarkable.

Physical examination upon admission

Physical examination revealed that her blood pressure was 141/90 mmHg,
temperature was 36.5 °C, pulse rate was 92 bpm and respiratory rate was 18 breaths/min. The uterine height was 24 cm and abdominal circumference was 96 cm. Fetal weight was estimated to be 800 g.

**Laboratory examinations**

On the 1st day of admission, routine blood examination showed a white blood cell count of $8.43 \times 10^9/L$, red blood cell count of $3.37 \times 10^{12}/L$ and platelet count of $86 \times 10^9/L$. An examination of blood coagulation function showed a D-dimer level of 1309 ng/mL (fibrinogen equivalent units). Liver and renal function examinations showed decreased albumin (33 g/L) and increased lactate dehydrogenase (345 U/L), urea nitrogen (9.1 mmol/L) and uric acid (539 μmol/L) with normal levels of alanine transaminase (17 U/L) and aspartate aminotransferase (32 U/L).

**Imaging examinations**

Color Doppler ultrasound examination at admission showed a second trimester pregnancy equivalent to 26 wk of gestation as well as normal fetal movement and a fetal heart rate of 160 bpm. The fetal head was located at the uterine fundus. The placenta of Grade I was in the anterior uterine wall. The fetal weight was estimated as 790 g and conditions of the fetus growth were as following: biparietal diameter: 6.6 cm; femur length: 4.6 cm; humeral length: 4.5 cm; head circumference: 24.8 cm; and abdominal circumference: 20.1 cm. Systolic/diastolic ratio of the umbilical artery and the fetal middle cerebral artery was 3.10 and 3.30, respectively. The amniotic fluid index was 12.9 cm.

**FINAL DIAGNOSIS**

The patient was primarily diagnosed with severe pre-eclampsia according to her clinical manifestations and laboratory results on admission.

**TREATMENT**

Other relevant examinations were completed after admission and medications including magnesium sulfate, labetalol and glucocorticoid were prescribed for spasmolysis, antihypertension and promotion of fetal lung maturation. Magnesium sulfate was administered with the loading dose of 5.0 g, followed by the 15.0-20.0 g pumped every day upon admission. The patient’s vital signs as well as fetal movement and heart rate were closely monitored to assess disease status. However, her blood pressure remained higher than normal with a maximum of 166/98 mmHg and the lower limbs showed obvious edema in the 25th h.

On the 3rd day morning, the 24-h proteinuria of the 2nd day after admission was reported as 10311.0 mg. We suspected there was an underlying autoimmune disease and then prescribed an immunological examination. In the afternoon of the 3rd day (47th h of admission), the lupus anticoagulant assays showed that the standardized ratio of dilute Russell’s viper venom time and silica clotting time were increased at 2.40 and 2.06, respectively. The dsDNA antibody, ACL-immunoglobulin (Ig) G and ACL-IgM were also elevated (61.5, 76.5 and 83.9 IU/mL, respectively). Positivity for dsDNA antibody, anti-nuclear antibody, anti-Sjögren’s syndrome-related antigen A antibody, anti-nucleosome antibody and decreased levels of complement C3 and C4 were also observed. One hour later, the ultrasonography of the lower limbs showed mural thrombus and stenosis of the bilateral popliteal veins. The underlying SLE flare and antiphospholipid syndrome were indicated and nadroparin was administered then.

However, the disease developed so rapidly and on the third night (54th h of admission), the fetal heart monitoring showed 110 bpm with a non-reactive pattern. Ten minutes later, the patient presented with blurred vision and involuntary convulsion of her entire body but was conscious and able to answer questions. Her vital signs at that time revealed a temperature of 37.1 °C, pulse rate of 94 bpm, respiratory rate of 17 breaths/min and elevated blood pressure of 172/102 mmHg. When the patient showed convulsion, magnesium sulfate of 1.5 g/h was pumped continuously and was administered with the purpose of spasmolysis for 3 d since admission. We did not consider the superaddition of magnesium sulfate in case of magnesium poisoning. In addition, thrombosis in both lower limbs indicated to us that the convulsion may also be caused by a potential cerebral embolism and hemorrhage besides preeclampsia. So urapidil and mannitol were used to reduce blood pressure as well as intracranial pressure. Her blood pressure decreased to
166/100 mmHg with slight convulsions and blurred vision.

Meanwhile, we informed the patient and her families of the disease status and the following treatment plan. However, considering the small gestational age of 27+2 wk and for fear of low infant survival rate, they did not have high expectations for the premature infant and decided not to deliver emergently. Furthermore, the head magnetic resonance imaging showed long T1 and T2 signals in the frontoparietal lobe, basal ganglia and pons, which indicated posterior reversible encephalopathy syndrome. Therefore, we monitored the maternal and fetal condition besides medications and consulted with the vascular surgeon for preparations of the inferior vena cava filter.

On the fourth morning (63rd h of admission), the blood biochemical testing and routine blood examination were carried out for further evaluation of the disease status, which indicated high lactic acid dehydrogenase of 318 U/L and increased white blood cell count of 10.07 × 10⁹/L and decreased red blood cell, hemoglobin and platelet count of 2.99 × 10¹²/L, 101 g/L and 84 × 10⁹/L, respectively. One hour later (64th h of admission), the fetal heart was not detected, and emergent ultrasonography was performed, which showed intrauterine death and pleural effusion in the fetus with an estimated gestational age of 26+ wk. In the 68th h, the patient underwent surgery consisting of inferior vena cava filter implantation for prevention of the potential occurrence of pulmonary embolism and subsequent cesarean section followed by hydrocortisone therapy. The dead fetus weighing 980 g was delivered. Methylprednisolone was prescribed during the postoperative period along with magnesium sulfate and enoxaparin.

### OUTCOME AND FOLLOW-UP

Laboratory testing on the third postpartum day revealed an increased white blood cell count and decreased red blood cell count, hemoglobin, platelet count and prothrombin time. On the sixth postoperative day, 24-h urinary protein decreased to 8463.0 mg and complement C3 was slightly lower than normal at 68.10 mg/dL with normal C4 and anti-dsDNA, which improved significantly compared with antepartum values. The patient’s hypertension improved and was in the normal range without recurrence of convulsions. Oral prednisone acetate (50 mg) was continued for SLE control. The patient was discharged on the 13th postoperative day with further follow-up in the Department of Rheumatology.

### DISCUSSION

The relationship between pregnancy and SLE is a matter of great concern and is mainly related to the effect of pregnancy on SLE and the impact of SLE on adverse pregnancy outcomes. Pregnancy is considered a high-risk period for patients with SLE, and there is no consensus on whether pregnancy increases the risk of SLE flares. Although the prognosis of patients with SLE has significantly improved and is no longer a contradiction for pregnancy due to continuous developments in obstetrics and rheumatology, pregnancy is still challenging with a high risk of maternal and fetal complications, such as hypertensive disorders, fetal loss, preterm birth, intrauterine growth retardation and neonatal lupus. Pre-eclampsia is one of the most common complications in pregnant patients with SLE. However, it is difficult to distinguish pre-eclampsia and active SLE in clinical practice as clinical manifestations such as hypertension, proteinuria and impaired renal function often occur in both conditions.

In the present study, we report a patient with pre-eclampsia as the initial manifestation of SLE during pregnancy. Such cases are rarely reported; thus, we comprehensively searched the relevant literature in PubMed from the database establishment to June 2019 and identified a total of eight published studies involving nine cases. The clinical characteristics and information on all included patients are summarized in Table 1. All of these patients were diagnosed with pre-eclampsia during pregnancy with new-onset SLE. Three patients (plus the present case) had SLE before delivery and six patients developed SLE in the postpartum period. In one study, the time of SLE diagnosis was unclear, but the patient showed SLE-related manifestations immediately after delivery. The mean age of the included patients was 29 years and ranged from 20 to 35 years. The most common pregnancy outcome was preterm delivery, which occurred in six patients. In addition, two patients developed abortion, and two had term delivery. Only one case of intrauterine death was observed. Maternal death did not occur, but the following pregnancy
complications in addition to pre-eclampsia and SLE were reported: Eclampsia, acute fatty liver, HELLP syndrome, acute myocardial infarction, acute heart failure, pulmonary edema, lupus nephritis, vasculitis, thrombosis, dilated cardiomyopathy, nephrotic syndrome, thrombocytopenic purpura and antiphospholipid syndrome. Lupus nephritis is a common complication and indicates the high incidence of renal involvement. Besides positive immunological examinations, symptoms supporting the diagnosis of SLE were as follows: Fever, skin rash and macules, oral ulcer, arthritis, proteinuria, hematuria, anemia, thrombocytopenia, leukopenia, renal disorder, convulsion and thrombus.

Of the ten reported cases, only two patients were diagnosed with SLE prior to the diagnosis of pre-eclampsia, and pre-eclampsia-related symptoms were absent on initial admission. The remaining eight patients initially manifested with pre-eclampsia before the diagnosis of SLE. In these eight patients, such as edema, proteinuria, hypertension and seizure, are common in pre-eclampsia, which made it difficult to distinguish the underlying SLE from pre-eclampsia. However, the typical manifestations of SLE (such as rash, arthritis or thrombus) and severe complications (such as vasculitis, thrombocytopenic purpura or lupus nephritis) occurred as the disease progressed and appeared as SLE. Furthermore, positive immunological test results (especially anti-dsDNA and antinuclear antibodies) further contributed to the diagnosis of SLE. In addition, as renal involvement often occurs in both pre-eclampsia and SLE, it is very important to distinguish between pre-eclampsia and renal damage caused by SLE. Patients with SLE often have a low level of C3 and increased dsDNA antibody in the blood, both of which are found in pre-eclampsia patients. Moreover, proteinuria rapidly decreases after delivery in pre-eclampsia, but is present or even increases in patients with renal disorder due to SLE.

Improvements in maternal and fetal outcomes in SLE patients have been achieved in the past few decades[12], but is still a great challenge for both obstetricians and rheumatologists. Multidisciplinary coordination including a comprehensive assessment before conception, close monitoring during pregnancy as well as termination of pregnancy at the appropriate time is essential for optimal prognosis. Once a patient with SLE becomes pregnant, regular prenatal examinations and monitoring per the following are necessary for us to learn the disease process: (1) Whether there is the maternal clinical manifestations that indicate the SLE flare, such as fever, facial erythema, arthralgia or photosensitivity; (2) Regular blood, urine, hepatic, renal and immunological analysis including anti-nuclear antibody, anti-dsDNA, ACL lupus, complement C3 and C4 and lupus anticoagulant assays; and (3) Regular ultrasound for detection of the growth and heart developments of the intrauterine fetus.

In particular, when SLE is complicated with pre-eclampsia, it is crucial to differentiate these disorders as each condition requires different treatment. Strict attention to symptoms and immunological tests is necessary for a definite diagnosis and timely treatment. In our case, hypertension, edema in both legs and proteinuria led to the diagnosis of pre-eclampsia and treatment with spasmolysis and antihypertensive therapy. Immunological tests were conducted to determine whether underlying SLE was present in view of the patient’s severe proteinuria. The unrelieved symptoms by treatment for pre-eclampsia and the results of immunological tests along with findings such as thrombosis and convulsions contributed to the diagnosis of an SLE flare and antiphospholipid syndrome. Fetal distress developed following suspected lupus encephalopathy. Regrettably, intrauterine death occurred even though an emergency cesarean section was performed. However, the patient had a good prognosis following postpartum glucocorticoid and anticoagulation therapy.

CONCLUSION

New-onset SLE during pregnancy and in the postpartum period is rare and difficult to differentiate from pre-eclampsia. Close attention should be paid to the symptoms, and timely immunological examinations should be performed, especially in patients with an initial diagnosis of pre-eclampsia and underlying SLE, which are essential for a rapid diagnosis and effective treatment.
Table 1 Case reports of pre-eclampsia with new-onset systemic lupus erythematosus during pregnancy

| Ref. | Age in yr, gravity, parity | Initial symptoms | Onset time of symptoms | Time of pre-eclampsia diagnosis | Symptoms supporting SLE diagnosis | Time of SLE diagnosis | Positive antibodies | Other pregnancy complications | Treatment of SLE | Fetal outcome | Birth gestation, fetal weight in g, and delivery method |
|------|---------------------------|------------------|------------------------|-------------------------------|---------------------------------|-----------------------|---------------------|-----------------------------|----------------|-------------|-----------------------------------|
| Minakami et al[8], 1994 | 34 G4P2 26 G1P0 | Facial rash, cold fingers, high fever | Early first trimester | NS | Facial rash, discoid rash, oral ulcer, arthritis, proteinuria | Before delivery | Anti-dsDNA, anti-Sm, ANA | Eclampsia, acute fatty liver, AMI | NS | NS | 14 wk, Supravaginal amputation |
| Hildbrand et al[9], 2005 | 34 G5P3 22 G1P0 | Severe dyspnea, hypertension, acute left heart failure | Immediately after delivery | NS | Anemia, thrombocytopenia, proteinuria | NS | Anti-dsDNA, ANA, anti-cardiolipin | Acute heart failure | Prednisone, cyclophosphamide | Live birth | 36 wk, 1640 g, NS |
| Yang et al[10], 2006 | 31 G1P0 | Skin rash, lower leg edema, dizziness, palpitation, leukopenia | 26 wk of gestation | 38 wk of gestation | Skin rash, leukopenia, proteinuria | After delivery | Anti-dsDNA, ANA | Pulmonary edema after delivery | Prednisolone, hydroxychloroquine, methylprednisolone, azathioprine, colchicine | Live birth | 33 wk, 1420 g, cesarean section |
| Matsuo et al[11], 2007 | 27 NS 26 G1P0 | Proteinuria, pre-eclampsia | 17 wk of gestation | 31 wk of gestation | Continuous proteinuria, hematuria | 12 mo after delivery | Anti-dsDNA, ANA | Lupus nephritis | Prednisolone, cyclosporine | Live birth | 31 wk, 1214 g, cesarean section |
| Borahay et al[12], 2009 | 20 G1P0 | Hypertension, headache, history of seizure | 39 wk of gestation | 39 wk of gestation | Fever, purpuric macules at the fingers, leukopenia, anemia, proteinuria | >18 d after delivery | Anti-dsDNA, ANA | Leukocytoelastic vasculitis, seizure, partial thrombosis of the proximal left transverse sinus | Methylprednisolone, enoxaparin, prednisone, hydroxychloroquine | Live birth | 39 wk, NS |
| Stepanko và et al[13], 2009 | 26 G1P0 | Pre-eclampsia, HELLP syndrome | 31 wk and 2 d of gestation | 31 wk and 2 d of gestation | Proteinuria, anemia, thrombocytopenia, fever | >3 wk after delivery | Anti-dsDNA, ANA | HELLP syndrome, dilated cardiomopathy, NYHA class 3-4, lupus nephritis | Plasma exchange, steroids, cyclophosphamide, mycophenolate mofetil | Live birth | 31 wk and 2 d, 1900 g cesarean section |
| Miyamoto et al[14], 2014 | 32 G1P0 | Pre-eclampsia | 29 wk of gestation | 29 wk of gestation | Thrombocytopenia, proteinuria, anemia | Anti-dsDNA, ANA, anti-Sm, anti-RNP | NS | Prednisone | Live birth | 29 wk, 1048 g, cesarean section |
Huang PZ et al. Pre-eclampsia and new-onset systemic lupus erythematosus

| Karacha- lios 2018 | 35 G2P1 | Edema in both legs, face and neck, history of RA for 6 yr and gestational hypothyroidism
|--------------------|---------|---------------------------------------------------------|
| Current case       | 28 G1P0 | Hypertension, edema in both legs, proteinuria
|                   |         | 27 wk of gestation                                      |
|                    |         | 27 wk of gestation                                      |
|                    |         | Anemia, fever, convulsion, dyspnea, blurred vision, thrombus in bilateral popliteal veins, renal disorder |
|                    |         | Before delivery                                          |
|                    |         | Anti-dsDNA, ANA                                         |
|                    |         | Lupus nephritis, antiphospholipid syndrome               |
|                    |         | Nadroparin, Enoxaparin, hydrocortisone, methylprednisolone |
|                    |         | Intrauterine death                                      |
|                    |         | 27 wk and 3 d, 980 g, cesarean section                 |

|                   |         | Postpartum nephrotic syndrome, lupus nephritis          |
|                   |         | Cyclophosphamide, azathioprine, methylprednisolone     |
| Live birth        |         | 34 wk and 6 d, 2340 g, cesarean section               |

AME: Acute myocardial infarction; ANA: Anti-nuclear antibody; AnuA: Anti-nucleosome antibody; anti-SSA: Anti-Sjögren’s syndrome-related antigen A antibody; NS: Not stated; RA: Rheumatoid arthritis; RNP: Ribonuclear protein; SLE: Systemic lupus erythematosus; NYHA: New York Heart Association.

REFERENCES

1. Pons-Estel GJ, Alarcón GS, Scaife L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. *Semin Arthritis Rheum* 2010; 39: 257-268 [PMID: 19136143 DOI: 10.1016/j.sar.2008.10.007]

2. Lissevskaya I, Murphy G, Isenberg D. Systemic lupus erythematosus. *Lancet* 2014; 384: 1878-1888 [PMID: 24861804 DOI: 10.1016/S0140-6736(14)60128-8]

3. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. *Am J Obstet Gynecol* 2008; 199: 127.e1-127.e6 [PMID: 18456233 DOI: 10.1016/j.ajog.2008.03.012]

4. Minakami H, Idei S, Koike T, Tamada T, Yasuda Y, Hirota N. Active lupus and preeclampsia: A life threatening combination. *J Rheumatol* 1994; 21: 1562-1563 [PMID: 7983665]

5. Yang MJ, Cheng MH, Lin HY. Onset of systemic lupus erythematosus during pregnancy. *J Chin Med Assoc* 2006; 69: 130-133 [PMID: 16599019 DOI: 10.1016/S1726-4901(09)70191-1]

6. Matsu S, Uchida E, Shimagi R, Nishihara G. A case of a pregnant woman developing systemic lupus erythematosus during pregnancy. *Clin Nephrol* 2007; 67: 331-332 [PMID: 17542344 DOI: 10.5414/cnp67331]

7. Borahay MA, Kelly BC, Harirah HM. Systemic lupus erythematosus presenting with leukocytoclastic vasculitis and seizure during pregnancy. *Am J Perinatol* 2009; 26: 431-435 [PMID: 19326323 DOI: 10.1055/s-0029-1214241]

8. Stepanková J, Birgelova M, Honsova E, Tesa R, Vrbska J, Vlklicky O. Preeclampsia, dilated cardiomyopathy and renal failure as the first manifestation of systemic lupus erythematosus: a case report. *Clin Rheumatol* 2009; 28: 343-345 [PMID: 19802775 DOI: 10.1007/s00296-008-1061-3]

9. Miyamoto T, Hoshino T, Hayashi N, Oyama R, Okanomiya A, Kitamura S, Ohtake N, Suga M, Miyamoto K, Takaoka A, Aoki T, Imamura Y, Nagano S, Kitai M. Preeclampsia as a Manifestation of New-Onset Systemic Lupus Erythematosus during Pregnancy: A Case-Based Literature Review. *AJP Rep* 2016; 6: e62-e67 [PMID: 26929873 DOI: 10.1055/s-0035-1566245]

10. Karachalios T, Bakas P, Beta A, Deligeoroglou E. Postpartum nephrotic syndrome related to new onset of systemic lupus erythematosus: A case report. *Case Rep Womens Health* 2018; 20: e0083 [PMID: 30425933 DOI: 10.1016/j.crwh.2018.e0083]

11. Hildbrand P, Eiggenmann C, Gugger M, Marti HP, Hullin R. Pre-eclampsia with acute heart failure postpartum as primary manifestation of systemic lupus erythematosus. *Eu J Heart Fail* 2005; 7: 1057-1058 [PMID: 16271444 DOI: 10.1016/j.ejhf.2004.11.012]

12. Clark CA, Spitzer KA, Laskin CA. Decrease in pregnancy loss rates in patients with systemic lupus erythematosus over a 40-year period. *J Rheumatol* 2005; 32: 1709-1712 [PMID: 16142865]
